Sheng Ma

Sheng Ma is the dried rhizome of Cimicifuga foetida L. (syn. Actaea cimicifuga L.), a perennial herbaceous plant in the family Ranunculaceae. In the traditional TCM classification system, Sheng Ma is considered pungent and sweet in flavor with a slightly cold nature. It enters the Lung, Spleen, Stomach, and Large Intestine meridians, giving it a central role in formulas that address exterior Wind-Heat patterns, Spleen Qi sinking, and Heat-toxicity conditions.

Botanical description: Cimicifuga foetida is a tall, herbaceous perennial reaching 1–2 meters in height. It has a stout, dark brown rhizome with numerous fibrous roots. The stem is erect, cylindrical, and often purplish-brown. The leaves are large, 2–3 times ternately compound, with ovate to rhomboid leaflets that are coarsely toothed. The plant produces small, greenish-white flowers in long, branched panicles (June–August), and the fruit is a small follicle containing several seeds. The rhizome, which is the medicinal part, is dark brown externally, irregularly shaped, and exhibits a yellowish-white to pale brown cross-section when cut. The dried slices are characteristically dark brown, with a distinctive rough texture and a slightly aromatic odor.

Habitat and cultivation: C. foetida is native to East Asia, including China, Mongolia, and parts of Siberia. In China, the primary producing regions include Sichuan, Yunnan, Gansu, Shaanxi, and Qinghai provinces. The plant prefers moist, well-drained soils in mountainous regions, typically growing at elevations of 1,500–3,000 meters along forest margins, grassy slopes, and stream banks. The rhizomes are harvested in autumn (September–October), cleaned of soil and fibrous roots, and dried in the sun or at low temperature. The dried rhizomes are then cut into slices for medicinal use. The quality of Sheng Ma is assessed based on its thickness, color, and aroma, with thicker, darker, and more aromatic slices considered superior.

Quality markers: The Chinese Pharmacopoeia specifies that high-quality Sheng Ma should have a dark brown to blackish-brown exterior, a yellowish-white to pale brown cross-section, and a slightly bitter taste with a characteristic aroma. The rhizome should be thick, solid, and free from mold or insect damage. In some regional standards, the content of ferulic acid and isoferulic acid are used as chemical markers for quality control of commercial Sheng Ma preparations. The pharmacopoeia also recognizes two other species — Cimicifuga dahurica (Turcz.) Maxim. and Cimicifuga heracleifolia Kom. — as equivalent sources for Sheng Ma, withC. foetida being the primary species.

In the traditional Chinese medicine theoretical framework, Sheng Ma is understood in terms of its effects on specific patterns of disharmony (zheng). Because Sheng Ma enters the Lung, Spleen, Stomach, and Large Intestine meridians and has a pungent, sweet, and slightly cold quality, it is traditionally indicated for a range of patterns involving exterior Wind-Heat, Spleen Qi sinking, and Heat-toxicity.

Releasing the exterior and dispersing Wind-Heat: Sheng Ma is traditionally used in TCM as a pungent, cool exterior-releasing herb. Its pungent flavor allows it to open the pores and disperse exterior pathogens, while its slightly cold nature helps clear Heat. It is particularly indicated for Wind-Heat patterns presenting with fever, headache, sore throat, red eyes, and a floating rapid pulse. Sheng Ma is considered especially effective when the Wind-Heat affects the head, face, and eyes. It is commonly combined with Ge Gen (Kudzu root) and other exterior-releasing herbs in formulas targeting Wind-Heat patterns.

Lifting Yang Qi and treating sinking Qi: One of the most distinctive traditional uses of Sheng Ma in TCM is its ability to lift sinking Yang Qi. In TCM theory, the Spleen is responsible for ascending the clear Qi to the upper body. When Spleen Qi is deficient, this ascending function fails, leading to "Spleen Qi sinking" — a concept that encompasses symptoms such as chronic diarrhea, rectal or uterine prolapse, a bearing-down sensation in the abdomen, chronic fatigue, and poor appetite. Sheng Ma is considered one of the key herbs for lifting sinking Qi, almost always used in combination with Huang Qi (Astragalus) and Chai Hu (Bupleurum), as in the classical formula Bu Zhong Yi Qi Tang. This combination is one of the most clinically important herb pairs in TCM for addressing Qi deficiency with sinking.

Clearing Heat and resolving toxicity: Sheng Ma is traditionally used for various Heat-toxicity patterns, including sore throat, swollen gums, mouth ulcers, and skin eruptions. In TCM, Heat-toxicity is a concept that describes severe Heat accumulation with inflammatory or infectious manifestations. Sheng Ma is believed to clear Heat and resolve toxicity, particularly in the head and face region. It is traditionally used in the early stages of measles and other eruptive febrile diseases where the rash fails to surface properly. In these contexts, Sheng Ma is combined with Ge Gen and other herbs that promote the eruption of the rash.

Classical literature references: The Shen Nong Ben Cao Jing (Divine Farmer's Materia Medica Classic, circa 200 CE) classified Sheng Ma as an upper-grade herb and recorded its traditional use for "clearing toxins, expelling all kinds of evil Qi, and treating sore throat, headache, and toxic swellings." The Ben Cao Gang Mu (Compendium of Materia Medica, 1596 CE) by Li Shizhen noted Sheng Ma's ability to "lift the clear Yang, resolve toxins, and disperse Wind-Heat." Li Dongyuan (Li Gao), the founder of the School of Tonifying the Spleen and Stomach, extensively used Sheng Ma in his formulas for lifting sinking Qi, particularly in Bu Zhong Yi Qi Tang.

Sheng Ma contains a range of bioactive compounds that have been the subject of pharmacological investigation. The following overview summarizes the major chemical constituents identified in the rhizome of Cimicifuga foetida and what is currently known about them from published research.

Ferulic acid and isoferulic acid: Ferulic acid and its isomer isoferulic acid are phenolic compounds that are among the most well-studied constituents of Sheng Ma. They have been investigated in pre-clinical research for their anti-inflammatory, antioxidant, and analgesic properties. These compounds are thought to contribute to the overall anti-inflammatory activity of Sheng Ma. They are also used as chemical markers for quality control of Sheng Ma in pharmacopoeial standards. However, the clinical relevance of these compounds in the context of whole-herb Sheng Ma preparations is not well established, as most evidence comes from in-vitro and animal studies.

Cimicifugosides (triterpenoid glycosides): Cimicifugosides are a class of cycloartane-type triterpenoid glycosides that are relatively specific to the Cimicifuga genus. These include cimicifugoside H-1, H-2, and related compounds. Cimicifugoside H-2 has been investigated in pre-clinical studies for potential anti-inflammatory and anti-tumor activities, including molecular docking studies suggesting it may act as an inhibitor of IKK1/alpha. A 2026 study (PMID: 42409335) reported the isolation of three new cimicifugosides (cimibiosides A-C) from C. foetida. Most research on these compounds remains at the pre-clinical stage.

Triterpenoids: Sheng Ma contains various triterpenoid compounds, including actein and related structures. Actein has been studied for its potential anti-obesity effects in animal models (PMID: 39922317), where it was found to modulate linoleic acid metabolism. Other triterpenoids from Sheng Ma have been investigated for their effects on bone metabolism, with some studies suggesting potential anti-osteoporotic properties. The clinical significance of these compounds in whole-herb preparations is not well understood.

Other constituents: Sheng Ma also contains caffeic acid, salicylic acid derivatives, sterols, and various other secondary metabolites. A 2025 study (PMID: 40872800) identified caffeic acid as a bioactive component of C. foetida with SARS-CoV-2 entry inhibitory activity. Most research on these secondary compounds remains at the pre-clinical stage, and their specific contributions to the pharmacological profile of whole-herb Sheng Ma are not fully understood.

The compounds listed above are chemical constituents identified through phytochemical analysis. Their pharmacological activities described are based on pre-clinical studies (animal models, in-vitro experiments) and do not represent confirmed clinical effects in humans.

Sheng Ma is a core ingredient in several important classical formulas in the TCM tradition for lifting sinking Qi, releasing Wind-Heat, and clearing Heat-toxicity. Below are three key formulas that feature Sheng Ma as a primary or significant component, along with their traditional indications and the role Sheng Ma plays in each composition.

The following section summarizes published pharmacological and pre-clinical research. Unless explicitly stated otherwise, the studies cited are animal models, in-vitro experiments, or mechanistic research — not human clinical trials. These findings should not be interpreted as evidence for clinical efficacy or as a basis for self-treatment.

Anti-inflammatory and antioxidant effects: Ferulic acid and isoferulic acid, the principal phenolic compounds in Sheng Ma, have been studied for their anti-inflammatory and antioxidant properties in pre-clinical models. Research has shown that these compounds can inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6, and enhance antioxidant enzyme activity. These findings provide mechanistic insights but do not establish clinical efficacy for inflammatory conditions in humans.

Anti-osteoporotic effects: A 2025 study published in Phytomedicine (PMID: 40680333) investigated the effects of Cimicifuga foetida and C. racemosa on postmenopausal osteoporosis. The study found that both species prevented bone loss in animal models by inhibiting autophagy of osteoclasts via CB2R and ERalpha pathways. This suggests potential applications for bone health, but human clinical trials are needed to confirm these findings.

Anti-tumor potential: Several pre-clinical studies have investigated the anti-cancer potential of Sheng Ma compounds. A 2024 study in Nutrients (PMID: 39408228) reported that methanolic extracts of C. foetida induced G1 cell cycle arrest and apoptosis in glioma cells and inhibited metastasis. Another study identified a compound (KHF-16) from C. foetidathat suppressed breast cancer by inhibiting the NF-κB signaling pathway. Cimicifugoside H-2 has been studied via molecular docking as a potential IKK1/alpha inhibitor (Biomolecules, 2024, PMID: 39062574). All of this evidence is pre-clinical, and no human studies have confirmed anti-cancer effects.

Antiviral effects: A 2025 study in Viruses (PMID: 40872800) screened medicinal herbs and identifiedCimicifuga foetida as a potent SARS-CoV-2 entry inhibitor, with caffeic acid identified as a bioactive component. This finding is exploratory and based on in-vitro assays; it does not constitute clinical evidence for treating COVID-19 or any viral infection.

Anti-obesity effects: A 2025 study in Biochemical Pharmacology (PMID: 39922317) investigated the anti-obesity effects of actein, a compound from C. foetida, in C57BL/6 mice. The study suggested that actein modulates linoleic acid metabolism to exert anti-adipogenic effects. While interesting, these findings are from animal models and do not constitute evidence for weight management in humans.

What the research does NOT show: Despite promising pre-clinical signals, the research on Sheng Ma and its active compounds does NOT demonstrate conclusive clinical efficacy for any specific disease in humans. There is no robust evidence from large-scale, randomized, placebo-controlled clinical trials that Sheng Ma can treat, cure, or prevent cancer, osteoporosis, viral infections, obesity, or any other medical condition. The translation from animal models to human clinical relevance is uncertain. This page does not endorse Sheng Ma as a treatment for any condition.

Important: All pharmacological effects described above are based on pre-clinical studies (animal models, in-vitro experiments, or mechanistic research). They do not constitute evidence of clinical efficacy in humans. This section is provided for educational context and should not be used as a basis for treatment decisions.

General safety profile: Sheng Ma is widely used in TCM practice and is generally considered to have a reasonable safety profile when used appropriately in formula combinations under professional guidance. However, like all herbal products, it is not free of risk. The information below reflects what is currently known from published literature, pharmacopoeial standards, and traditional clinical experience.

Yin deficiency with Heat: In traditional TCM theory, Sheng Ma is pungent, sweet, and slightly cold in nature. Its dispersing and ascending properties may theoretically further deplete Yin fluids in individuals with pre-existing Yin deficiency, particularly those presenting with Heat signs such as night sweats, dry mouth, a red tongue with little or no coating, and a thready rapid pulse. In such cases, Sheng Ma should be used with caution, typically in combination with Yin-nourishing herbs, and only under professional guidance.

Excessive Heat patterns: While Sheng Ma is used for clearing Heat, its dispersing nature is relatively mild compared to stronger Heat-clearing herbs. In patterns of excessive Heat with high fever, severe thirst, and a large forceful pulse, Sheng Ma may be insufficient as a primary herb and is typically used as an adjuvant alongside stronger Heat-clearing and toxin-resolving herbs. Its use in such patterns should be guided by professional pattern differentiation.

Pregnancy and lactation: Sheng Ma has a traditional reputation for potentially stimulating uterine contractions and is therefore generally contraindicated or used with extreme caution during pregnancy. Some sources advise avoiding Sheng Ma entirely during pregnancy, particularly in the first trimester. The safety of Sheng Ma during lactation has not been adequately studied in modern research. Sheng Ma should only be used during pregnancy under the direct supervision of a qualified healthcare professional.

Drug interactions: Pre-clinical data suggest that certain constituents in Sheng Ma, including ferulic acid and cimicifugosides, may affect the activity of hepatic cytochrome P450 enzymes, which could theoretically alter the metabolism of drugs processed through these pathways. There is also theoretical potential for additive effects when combined with anticoagulant or antiplatelet medications, given the reported effects of ferulic acid on platelet aggregation in pre-clinical studies. Additionally, some constituents of Sheng Ma have been studied for estrogenic activity, raising theoretical concerns about interactions with hormonal therapies. Clinical interaction data for whole-herb Sheng Ma are very limited. Consult a qualified healthcare professional before combining Sheng Ma with any prescription medications.

Reported side effects: Based on available reports, side effects associated with Sheng Ma are generally rare and mild when used at appropriate doses. Occasional reports include mild gastrointestinal discomfort (nausea, bloating), dizziness, or allergic reactions (skin rash) in sensitive individuals. At high doses, Sheng Ma has been reported to cause nausea and vomiting in some cases. Any suspected adverse effects should be reported to a healthcare professional.

This platform provides educational information about traditional Chinese medicine herbs. It does not recommend, endorse, or prescribe the use of Sheng Ma or any other herbal product for the treatment of any medical condition. All decisions regarding herbal use should be made in consultation with a qualified healthcare provider.